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A Viral ER-Resident Glycoprotein Inactivates
the MHC-Encoded Peptide Transporter
Hartmut Hengel,* Jens-Oliver Koopmann,² In the MHC class I pathway of antigen presentation,
antigenic peptides generated by cytosolic proteasesThomas Flohr,* Walter Muranyi,* Els Goulmy,³
must be translocatedby the ATP-dependent transporterGuÈ nter J. HaÈ mmerling,² Ulrich H. Koszinowski,*
associated with antigen processing (TAP) across theand Frank Momburg²
endoplasmic reticulum (ER) membrane for assembly*Max von Pettenkofer-Institut
into ternary MHC class I complexes (reviewed by Yew-Lehrstuhl Virologie
dell and Bennink, 1992; by Heemels and Ploegh, 1995;Genzentrum der Ludwig-Maximilians-UniversitaÈ t
and by Koopmann et al., 1997). TAP is a heterodimerMuÈ nchen
composed of two homologous proteins, TAP1 and81377 MuÈ nchen
TAP2, both encoded in the MHC. Both subunits areGermany
predicted to span the ER membrane 6±10 times with²Abteilung fuÈ r Molekulare Immunologie
small loops penetrating the cytosol and ER lumen andDeutsches Krebsforschungszentrum
to possess a large cytosolic domain containing an ATP-69120 Heidelberg
binding cassette. The transport of peptides by TAP re-Germany
quires two coupled but independent events. In the first³Department of Immunohematology and Blood Bank
step, the peptide is bound to the cytosolic face of TAP,University Hospital
before it is subsequently translocated in an ATP-depen-2300 RC Leiden
dent manner and released into the lumen of the ERThe Netherlands
(Androlewicz et al., 1993; Neefjes et al., 1993; Shepherd
et al., 1993; van Endert et al., 1994). Recently, the herpesSummary
simplex virus 1 (HSV-1) ICP47 protein was demonstrated
to inhibit the peptide transport by blocking the peptide-Human cytomegalovirus inhibits peptide import into
binding site of TAP (Ahn et al., 1996b; Tomazin et al.,the endoplasmic reticulum (ER) by the MHC-encoded
1996).TAP peptide transporter. We identified the open read-
The assembly of MHC class I heavy chain with b2ming frame US6 to mediate this effect. Expression of
and peptide is assisted by transient interactions withthe 21 kDa US6 glycoprotein in human cytomegalovi-
molecular chaperones in the ER. Calnexin has beenrus±infected cells correlates with the inhibition of pep-
shown to interact with free class I heavy chains (Degentide transport during infection. The subcellular local-
and Williams, 1991; Rajagopalan and Brenner, 1994),ization of US6 is ER restricted and is identical with
and calreticulin binds human class I/b2m dimers (Sadasi-TAP. US6 protein is found in complexes with TAP1/2,
van et al., 1996). MHC class I heterodimers associate
MHC class I heavy chain, b2-microglobulin, calnexin, with TAP via the TAP1 subunit (Androlewicz et al., 1994;calreticulin, and tapasin. TAP inhibition, however, is
Ortmann et al., 1994; Suh et al., 1994) mediated by anindependent of the presence of class I heavy chain
48 kDa ER glycoprotein, tapasin (Sadasivan et al., 1996).
and tapasin. The results establish a new mechanism
Binding of high-affinity peptides to class I molecules
for viral immune escape and a novel role for ER-resi-
leads to the dissociation of TAP±class I complexes and
dent proteins to regulate TAP via its luminal face.
the exit of ternary class I complexes from the ER (Ort-
mann et al., 1994; Suh et al., 1994).
Introduction The down-regulation of MHC class I expression during
permissive HCMV infection was attributed to two gene
Cytomegaloviruses (CMVs) belong to the b subfamily of regions of the HCMV genome, one of which is the gene
herpesviruses, which are large DNA-containing enve- US11 (Jones et al., 1995). We have recently described
loped viruses. Human CMV (HCMV) is an important that HCMV infection results in an inhibition of peptide
pathogen causing both acute and chronic infections in translocation into the ER despite augmented TAP ex-
the immunologically immature and in the immunocom- pression in HCMV-infected cells. This effect was not
promised host (Ho, 1982). CMV genes are expressed in mediated by the gene US11 and was found to be absent
a cascade fashion characteristic of herpesviruses during from cells infected with a HCMV deletion mutant, ts9,
the immediate-early (IE), early, and late phases of infec- lacking the genes US1 through US15 (Hengel et al.,
tion. CMVs have evolved specific functions to escape 1996). Ploegh and coworkers have elegantly demon-
cellular immune responses (reviewed by York, 1996). strated that the US11- and US2-encoded glycoproteins
Both HCMV and mouse CMV interfere with the surface target class I heavy chains from the ER to the cytosol
expression of major histocompatibility (MHC) class I for rapid proteolytic degradation (Wiertz et al., 1996a,
molecules and antigen presentation to CD81 T lympho- 1996b).
cytes at multiple checkpoints (Barnes and Grundy, 1992; Here we describe the identification of the HCMV gene
Del Val et al., 1992; Hengel et al., 1995; Jones et al., US6 encoding a 21 kDa glycoprotein preventing peptide
1995). In HCMV-infected fibroblasts, the formation of translocation by TAP. In US6-expressing HeLa cells,
ternary class I heavy chain±b2-microglobulin (b2m)± MHC class I molecules do not acquire peptides and lack
peptide complexes is drastically reduced during the transport out of the ER. The subcellular distribution of
early and late phase of infection (Beersma et al., 1993; gpUS6 shows a pattern identical with TAP1, and gpUS6
maintains complete sensitivity to endoglycosidase HYamashita et al., 1993; Warren et al., 1994).
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(endo H), indicative of ER-resident proteins. gpUS6 is conformation-dependent monoclonal antibody (MAb)
W6/32 detecting b2m-associated class I heavy chainsdemonstrated to associate with the TAP±tapasin±MHC±
calreticulin complex as well as with calnexin. gpUS6 (Parham et al., 1979) or MAb HC10 recognizing nonas-
sembled class I molecules (Stam et al., 1986). Half ofprevented the peptide import into microsomes prepared
from mutant cell lines deficient for either MHC class I each precipitate was subjected to endo H digestion and
separated by SDS polyacrylamide gradient gel electro-or for tapasin, indicating that these molecules are not
required to block TAP. Both the inhibition of TAP via its phoresis (SDS-PAGE). As depicted in Figure 1D, the
formation of MHC class I complexes that remained endoER luminal face and the retained peptide binding to
TAP in the presence of gpUS6 underscore a markedly H sensitive was diminished in HeLa-US6 cells. Most
strikingly, almost all MHC I complexes formed in HeLa-different behavior from ICP47 of HSV-1 and establish a
new molecular mechanism to regulate this transporter. US6 transfectants were unstable at 378C, while in HeLa
control cells most b2m-associated class I heavy chains
remained stable at 378C and aquired resistance to endoResults
H cleavage. Conversely, the level of nonassembledMHC
class I heavy chains recognized by MAb HC10 was in-HCMV US6 Affects MHC Class I Surface Expression,
creased in US6-expressing HeLa cells compared to con-Antigen Presentation to CD81 Cytotoxic
trols (Figure 1D, bottom). Taken together, the resultsT Lymphocytes, and Peptide
confirm defective peptide loading onto heavy chain/b2mTransport into the ER
heterodimers in the presence of the US6 protein re-
The absence of peptide transport inhibition in human
sulting in a reduced exit of stably formed MHC class I
fibroblasts permissively infected with the HCMV AD169±
molecules from the ER.
derived deletion mutant ts9 suggested that the putative
inhibitor may reside within the gene region lacking in
ts9, that is, US1 through US15. To search for the viral Synthesis of US6 Protein Correlates with Inhibition
of Peptide Transport during Permissivegenes that mediate TAP inhibition, we cloned and stably
expressed the open reading frames US1, US2, US3, HCMV Infection
As in other herpesviruses, CMV replication is tightly reg-US4, US5, US6, US7, US8, US9, US10, US12, and US13
in HLA-A21 293 kidney cells and HeLa cells. The ulated in a multistep process. During productive infec-
tion, cellular transcription factors initiate the transcrip-transfectants were screened for antigen presentation to
HLA-A2 allospecific CD81 cytotoxic T lymphocyte (CTL) tion of IE genes that induce the expression of several
sets of early genes, most abundantly expressed 6±60clones (Goulmy et al., 1984), class I surface expression,
and TAP-mediated peptide transport. The isolated hr postinfection. Early proteins are required for viral DNA
replication followed by the synthesis of late proteinsgenes US2 (data not shown) and US6 proved to reduce
both surface expression of class I molecules and recog- (approximately 48±96 hr postinfection), many of which
are incorporated into the virion or aid the process ofnition by CD81 CTL (Figures 1A and 1B). In contrast, the
surface expression of CD44 molecules on HeLa cells progeny assembly. The kinetics of US6 protein expres-
sion in HCMV wild-type strain AD169±infected fibro-was not affected by US6 expression (Figure 1B). In HeLa
or 293 cells stably transfected with US6 or infected with blasts during the course of permissive infection was
assessedafter metabolic labeling and immunoprecipita-a recombinant vaccinia virus expressing US6, a drastic
reduction of ATP-dependent peptide transport by TAP tion with a polyclonal rabbit antiserum raised against
synthetic peptide corresponding to amino acids 20±29was found (Figure 1C). This inhibition was similar to the
inhibition seen in transfectants stably expressing the of the US6 sequence. From parallel cultures of the same
experiment, ATP-dependent peptide translocation byTAP inhibitor ICP47 of HSV-1 (Figure 1C) (FruÈ h et al.,
1995; Hill et al., 1995). Likewise the US6 sequence TAP was assessed using the peptide RYWANATRSF.
As shown in Figure 1E, the continuous decline in peptidetagged with the hydrophilic FLAG sequence at the
C-terminus inhibited peptide translocation by TAP (Fig- transport correlated with US6 protein synthesis, which
was maximal at 72 hr postinfection. Pulse-chase experi-ure 1C). We conclude that HCMV US6 is able and suffi-
cient to interrupt the MHC class I pathway of antigen ments indicated that the US6 polypeptide has a half
time of approximately 3 hr (data not shown). We con-presentation by reducing the peptide translocation into
the ER. clude that US6 protein synthesis starts during the early
phase and reaches peak levels at 72 hr postinfection
in the late phase of the viral replication cycle, while,MHC Class I Molecules in HeLa-US6 Transfectants
inversely, TAP-dependent peptide translocation into theDo Not Aquire Peptides
ER is progressively decreased.
Peptide-filled MHC class I complexes are characterized
by stability at 378C in 1% NP40 lysate and transport
to the medial-Golgi where their carbohydrate moieties Subcellular Distribution of the US6 Protein
The putative amino acid sequence of US6 codes for aacquire resistance to cleavage by endo H (Townsend
et al., 1990). To determine whether MHC class I mole- type Ia transmembrane protein with a protein core of
21 kDa and a single potential N-linked glycosylation site.cules in HeLa-US6 transfectantsare loaded with peptide
or not, HeLa control cells and HeLa-US6 cells were met- To study the subcellular distribution of the US6 protein,
confocal laser scanning microscopy of US6-transfectedabolically labeled with [35S]methionine for 15 min and
lysed in 1% NP40 buffer. The lysates were split and HeLa cells was performed using an affinity-purified rab-
bit antiserum recognizing the luminal domain of the pro-aliquots chased for 60 min at 378C or 48C, respectively.
MHC class I molecules were precipitated with either the tein. In paraformaldehyde-fixed detergent-solubilized
TAP Inhibition by HCMV gpUS6
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Figure 1. US6 Expression Prevents CD81 T
Cell Recognition, MHC Class I Surface Ex-
pression, and MHC Class I Complex Forma-
tion Due to Inhibited Peptide Transport by
TAP
(A) 293 cells stably transfected with pcDNAI-
US6 plasmid or the vector alone were labeled
with 51Cr and tested in a 4 hr standard release
assay with graded number of effector cells.
The effectors were the HLA-A2 allospecific
CD81 CTL clones IE2 (circles) and JS132 (tri-
angles).
(B) Cytofluorometric analysis of MHC class I
surface expression of HeLa cells transfected
with pcDNAI-US6 and HeLa control cells.
Cells were stained with MAb W6/32 (bold
lines) or anti-CD44 MAb (narrow lines) fol-
lowed by goat-anti mouse IgG-FITC. Dotted
lines represent control staining with second
antibody only.
(C) ATP-dependent peptide translocation
was assessed for permeabilized HeLa cells
and individual US6 transfected clones (top
and middle) and 293 cells and 293-US6
transfectants, respectively (bottom). HeLa
cells were infected overnight with US6-
recombinant vaccinia virus or control vac-
cinia virus at a multiplicity of infection (moi)
of 3. Filled bars represent transport rates in
the presence of ATP; open bars in the ab-
sence of ATP for control. The data represent
means of duplicate values.
(D) Nontransfected and US6-transfected HeLa
cells were metabolically labeled for 15 min.
Lysates in 1% NP40 were either kept at 48C or incubated at 378C for 60 min prior
to immunoprecipitation of aliquots with MAb W6/32 (top) and MAb HC-10 (bottom).
Half of the precipitated molecules were digested with endo H or mock treated. s
indicates MHC class I molecules sensitive and r indicates MHC class I molecules
resistant to endo H cleavage. HC, MHC class I heavy chains.
(E) Kinetics of peptide translocation by TAP assessed with peptide RYWANATRSF
(triangles) during permissive infection of MRC-5 fibroblasts with HCMV AD169
(moi 5 5). In parallel cultures, the level of US6 expression in MRC-5 cells infected
with HCMV AD169 (moi 5 5) was determined by immunoprecipitation with anti-
US6 antiserum and analyzed by SDS-PAGE (top). US6 expression (circles) is shown
in arbitrary units after phosphoimager quantitation of the US6 bands. Peptide
transport is shown as the percentage inhibition of the transport rate (9.2%) obtained
with mock-infected cells.
cells a typical ER-like staining pattern was observed and with TAP1, which is primarily located in the ER and
can reach cisternae of the cis-Golgi (Kleijmeer et al.,(Figure 2A), while HeLa control cells were negative (data
not shown). The localization of US6 in the ER was con- 1990; Russ et al., 1995) (Figure 2B). The distribution
pattern of US6 clearly differed from that of the ER Golgifirmed by a nearly perfect colocalization with the ER
marker protein BiP (Vaux et al., 1990) (data not shown) intermediate compartment (ERGIC) marker ERGIC-p53
Immunity
626
a protein of 21 kDa (Figure 3A). Of these, only the 48,
44, and 21 kDa bands were found completely sensitive
to endo H, indicating N-linked glycosylation and reten-
tion of these molecules in the ER. To characterize the
gpUS6-associated proteins further, their pattern was
analyzed from the HeLa-US6 transfectant pretreated
with IFNg for 48 hr or not. This proved the polypeptides
of 70, 48, and 44 kDa to be inducible by IFNg while the
intensity of the other bands remained constant (data not
shown).
To identify the components of the US6 complex, the
immunoprecipitate recovered from a digitonin lysate of
HeLa-US6 cells was heated in NP40 lysis buffer con-
taining 1.5% SDS, resulting in release of the proteins
(Figure 3B, lane 1). After dilution to a final SDS concen-
tration of 0.15% and preclearing of anti-US6 antibodies,
reimmunoprecipitation was performed from the super-
natant. Reprecipitation with antibodies specific for TAP1
and TAP2 (Figure 3B, lane 2), free class I heavy chain
(Figure 3B, lane 3) and calnexin (Figure 3B, lane 4)
yielded prominent bands with the expected molecular
weight of the proteins in addition to a weaker 21 kDa
band corresponding to reassociated gpUS6. Reprecipi-
tation with an anti-calreticulin antibody (Figure 3B, lane
5) recovered no band corresponding to calreticulin but
minute amounts of gpUS6, whereas reprecipitation with
anti-BiP was negative (Figure 3B, lane 6). In an indepen-
dent reimmunoprecipitation experiment, antibodies rec-
ognizing tapasin (Ortmann et al., 1994; Sadasivan et al.,
1996) yielded a band of the appopriate size (48 kDa)
from US6 complexes present in a digitonin lysate (Figure
3C, lane 2). In addition, a protein of 12 kDa representing
b2m was precipitated from US6 complexes by MAbFigure 2. Subcellular Distribution of US6 Visualized by Confocal La-
ser Scanning Microscopy BBM1 (Figure 3C, lane 3). To decide whether calreticulin
HeLa-US6 transfectants were pretreated with 500 U/ml IFNg for 48 participates in the gpUS6 complex, an immunoprecipi-
hr before paraformaldehyde fixation and solubilization with 0.1% tate recovered by anti-calreticulin antibodies (Figure 3D,
NP40. Cells were double-stained with (A) anti-US6 antiserum and lane 1) was dissolved in 1.5% SDS and the supernatant
(B) anti-TAP1 MAb 1.28 and goat anti-rabbit IgG-FITC and goat anti-
precipitated with anti-US6 antibodies. As demonstratedmouse IgG-TRITC. HeLa-US6 cells were double stained with (C)
in Figure 3D, lane 3, this procedure yielded bands corre-anti-US6 antiserum and (D) mouse MAb G1/93 reactive with p53, a
sponding to TAP, tapasin, and MHC class I but alsomarker protein of the ERGIC. Second antibodies as in (A) and (B).
HeLa-US6 cells stained (E) with anti-US6 antibodies and (F) mouse small amounts of gpUS6.
MAb CM1A10 recognizing coat proteins of the Golgi. Second anti- In conclusion, the data suggest that gpUS6 interacts
bodies as above. with the recently described transient assembly complex
containing TAP1/2, tapasin, class I heavy chain, b2m,
and calreticulin (Sadasivan et al., 1996). In addition,
(Schweizer et al., 1990) (Figure 2D) and the staining gpUS6 associates with the ER-resident chaperone cal-
obtained with CM1A10, a coatomer-specific MAb bind- nexin. This interaction may be independent of the com-
ing to cis- and medial-Golgi cisternae (Palmer et al., plex formation with TAP, since previous studies indi-
1993) (Figure2F). The datadocumented a superimposed cated that in human cells calnexin is not associated
distribution of US6 and its target, TAP, within the cell and with the class I±TAP complex (Ortmann et al., 1994;
suggested that the US6 polypeptide isa transmembrane Sadasivan et al., 1996).
ER-resident protein.
gpUS6 Interacts with Multiple ER Proteins gpUS6 Does Not Prevent Peptide
Binding to TAPIncluding TAP1/2
To test whether US6 interacts directly with TAP, HeLa- The cytosolic TAP inhibitor ICP47 was shown to com-
pete with the ATP-independent binding of peptidesUS6 transfectants were incubated with interferon-g
(IFNg) to stimulate TAP synthesis and labeled overnight to the transporter (Ahn et al., 1996b; Tomazin et al.,
1996). Using a photoactivable radioiodinated 125I-TYDNKwith [35S]methionine before lysis in digitonin buffer. US6
protein was immunoprecipitated from lysates and re- TRA(Tpa) peptide, we tested whether thebinding of pep-
tides to TAP can occur in the presence of gpUS6. In-covered immune complexes were eluted and analyzed
by PAGE. Bands of approximate molecular weights of creasing amounts of the photopeptide were incubated
with streptolysin O (SLO)±permeabilized HeLa-US6 or97, 70, 55, 48, and 44 kDa were coprecipitated with US6,
TAP Inhibition by HCMV gpUS6
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Figure 3. Identification and Characterization
of US6-Associated ER Proteins
(A) HeLa and HeLa-US6 transfectants were
metabolically labeled overnight and lysed in
digitonine lysis buffer. gpUS6 was immuno-
precipitated by rabbit anti-US6 antiserum,
and proteins were separated by 10%±15%
PAGE. US6-associated proteins are indicated
by arrows. Immune complexes retrieved from
digitonin lysates were mock-digested or di-
gested with endo H. s indicates bands with
a mobility shift after endo H digestion.
(B) HeLa-US6 cells were metabolically la-
beled as described in (A) and lysed in digito-
nin lysis buffer. Material precipitated with
anti-US6 antiserum was heated and dis-
solved in 1% NP40/1.5% SDSbuffer. Proteins
not dissociated from the protein A Sepharose
pellet were analyzed on lane 1. Aliquots of
thesupernatant werereprecipitated with anti-
TAP1 MAb TAP1.28 and anti-TAP2 MAb
TAP2.70 (lane 2), rabbit anti±heavy chain anti-
serum (lane 3), anti-calnexin MAb AF8 (lane
4), rabbit anti-calreticulin antiserum (lane 5),
and rabbit anti-BiP antiserum (lane 6).
(C and D) HeLa-US6 cells were pretreated
with 500 U/ml IFNg before metabolically la-
beled as described in (A) and lysed in digito-
nin lysis buffer. (C) One aliquot of the lysate
was precipitated with anti-US6 antiserum.
The precipitate was heated and dissolved in
1% SDS. Proteins not dissociated from the
protein A Sepharose pellet were analyzed in
lane 1. Aliquots of the supernatant were re-
precipitated with rabbit anti-gp48 (tapasin)
(lane 2) antiserum and MAb BBM1 specific
for human b2m (lane 3). (D) The lysate was
precipitated with rabbit anti-calreticulin anti-
bodies. Aliquots of these immune complexes
were either directly analyzed (lane 1) or
heated and dissolved in 1% SDS. Proteins
not dissociated from the protein A Sepharose
pellet were analyzed in lane 2. The superna-
tant was reprecipitated with anti-US6 antise-
rum (lane 3).
HeLa control cells in the absence of ATP at 48C. Ultravio- LCL721.221 mutant cells (DeMars et al., 1985; Green-
wood et al., 1994; Grandea et al., 1995; Sadasivan etlet crosslinking and immunoprecipitation with TAP-spe-
al., 1996) and the microsomes were assayed for ATP-cific antibodies from HeLa-US6 cells resulted in bands
dependent peptide import (Figure 5). In the presence ofof about 70 kDa, the intensity of which was not reduced
US6, microsomes of both cell lines completely failed tocompared to the HeLa control (Figure 4) but was drasti-
accumulate glycosylated peptides, while translation ofcally reduced after addition of recombinant ICP47 pro-
Saccharomyces cerevisiae a-factor mRNA as a controltein, which blocks peptide binding to TAP (Figure 4,
had no effect. Thus, class I heavy chains and tapasinlanes 4 and 8). This result indicates that gpUS6 does not
are dispensable for the functional inactivation of TAP1/2.affect peptide binding to TAP. Furthermore, the ICP47-
Furthermore, this finding illustrates that in vitro trans-mediated competitive inhibition of peptide binding is
lated US6 protein is able to reach preformed TAP com-independent of the presence of gpUS6. Thus the mecha-
plexes to exert its blocking activity.nism employed by US6 for the blockade of peptide
transport is different from ICP47.
Discussion
gpUS6 Does Not Require MHC Class I Despite augmented levels of TAP expression, fibro-
and Tapasin to Block TAP blasts permissively infected with HCMV exhibit a down-
To address the role of class I heavy chains or tapasin modulation in the capacity to translocate peptides
for the inactivation of TAP1/2 by gpUS6, US6 protein was across the ER membrane. This effect is detectable not
translated in vitro in the presence of microsomes prepared earlier than 12 hr postinfection and progressively in-
from HLA-A2, -B2, -C1 tapasin-negative LCL721.220 creases during infection (Hengel et al., 1996). This kinet-
ics is consistent with the appearance of a viral inhibitor
Immunity
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Figure 4. gpUS6 Does Not Prevent Peptide Binding to TAP
SLO-permeabilized HeLa or HeLa-US6 cells were incubated with
titrated amounts of the photolabile peptide 125I-TYDNKTRA(Tpa)
without (lanes 1±3 and 5±7) or with recombinant ICP47 protein (lanes
4 and 8). After ultraviolet crosslinking, TAP1 and TAP2 molecules
were immunoprecipitated by MAb TAP1.28 and TAP2.70 and ana-
lyzed by SDS-PAGE.
Figure 5. Inhibiton of Peptide Transport by US6 Is Independent of
Tapasin and MHC Class I Heavy Chain
the expression of which is relatively low after the onset US6 protein was in vitro translated into microsomes of tapasin-
of the early phase and peaks in the late phase 72 hr deficient 721.220 cells and HLA-A, -B, -C±deficient 721.221 cells.
The transport capacity of microsomes was determined with glycosy-postinfection. Here we describe the US6 gene product
latable peptides 55 (RYWANATRSA) and 60 (RYWANATRSQ). Filledto cause the inhibition of TAP-mediated peptide trans-
bars represent in vitro±translated control mRNA, transport in theport. As a consequence of TAP inhibition by gpUS6
presence of ATP; open bars represent in vitro translation of US6
and other independent gene functions expressed earlier mRNA, transport in the presence of ATP; hatched bars represent
during HCMV infection (vide infra), the formation of MHC in vitro translation of control mRNA, no ATP added.
class I complexes, their transport to the cell surface and
antigen presentation to CD81 T cells is abolished in
HCMV-infected cells (Beersma et al., 1993; Yamashita to the stability of gpUS6 since the half-life of US6 is
reduced in tunicamycin-treated cells (H. H., unpublishedet al., 1993; Warren et al., 1994; Hengel et al., 1995).
Transient expression of the isolated US6 gene by recom- data). The complete sensitivity of gpUS6 to endo H
indicates efficient retention in the ER consistent withbinant vaccinia virus or stable expression of gpUS6 in
transfected cells consistently resulted in a diminished the superimposable immunofluorescence staining for
gpUS6 and the ER marker protein BiP. The perfect colo-peptide transport function of human cells. The maximum
of gpUS6 expression was found to occur at approxi- calization with TAP1 appears to make the latter a dedi-
cated target for gpUS6. Since gpUS6 does not containmately 72 hr postinfection, which perfectly matches the
slow kinetics of TAP inhibition. A HCMV deletion mutant, the C-terminal KKXX consensus motif for ER retention
of transmembrane proteins (Jackson et al., 1990), it ists9, lacking thegenomic region encompassing US6, was
previously shown not to impair peptide transport unclear by which mechanism gpUS6 is retained in the
ER. We have found a prominent association of gpUS6(Hengel et al., 1996). Finally, in cells expressing the
HCMV US11 (Hengel et al., 1996) or US2 genes (data with the ER-resident chaperone calnexin that associates
with incompletely folded glycoproteins through a lectin-not shown), which are sufficient to down-regulate MHC
class I expression, the peptide transport function is not like activity (Ou et al., 1993). In contrast to gpUS6 com-
plexes with TAP that are severely reduced or undetect-affected. We conclude that in all likelihood, gpUS6 rep-
resents the only relevant HCMV gene product mediating able in NP-40 lysates compared with digitonin lysates,
association of gpUS6 and calnexin is less affected byTAP inhibition in the course of HCMV infection.
The reduced transport capacity of gpUS6-expressing the stronger detergent NP-40 (data not shown). It is
conceivable that gpUS6 molecules containing as manycells is demonstrated in vitro using nonnatural peptide
sequences that are retained in the ER through an as 11 cystein residues slowly attain a mature conforma-
tion and that calnexin retains immature gpUS6 mole-N-linked carbohydrate. Our biochemical analysis of
HeLa-US6 cells provided evidence that the vast majority cules in the ER by high-affinity binding.
Although the functional phenotype of HSV-1 ICP47of class I molecules expressed in HeLa cells fails to be
loaded with peptides as indicated by lacking thermosta- and HCMV gpUS6 appears similar, these proteins utilize
entirely different mechanism for the inhibition of TAP.bility and ER retention. Thus, the impairment of peptide
transport is not restricted to selected peptide se- While the soluble 9 kDa protein ICP47 binds to the cyto-
solic face of TAP1/2 dimers with high affinity and inhibitsquences but appears to apply to the function of TAP in
general. Only a small minority of class I ligands may be peptide association with the transporter in a competitive
fashion (Ahn et al., 1996b; Tomazin et al., 1996), gpUS6generated in the ER lumen itself or get access to the
ER independent of TAP (reviewed by Momburg et al., does not interfere with peptide binding, which is an ATP-
independent and temperature-insensitive step thought1994a).
The US6 open reading frame encodes a type I trans- to precede the energy-consuming translocation of
bound substrate (van Endert et al., 1994). It is unknownmembrane protein of 21 kDa containing a single N-gly-
cosylation site. We found the whole population of gpUS6 how TAP facilitates vectorial transport of peptides vary-
ing greatly in their amino acid composition and lengthglycosylated. The carbohydrate moiety may contribute
TAP Inhibition by HCMV gpUS6
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against a concentration gradient (reviewed by Andro- where they are rapidly degraded by the proteasome
(Wiertz et al., 1996a,1996b). These genes areabundantlylewicz and Cresswell, 1996, and by Koopmann et al.,
1997). It can be envisaged that amphipathic membrane- expressed up to 24 hr postinfection but poorly tran-
scribed at later times (Jones and Muzithras, 1991; Ten-spanning segments form a pore that allows the transit
of hydrophilic substrates through the lipid bilayer. The ney and Colberg-Poley, 1991). By contrast, the appear-
ance of gpUS6 is maximal 48±96 hr postinfection whenenergy dependence of peptide translocation and the
presence of two nucleotide-binding cassettes within the other genes interfering with the MHC class I pathway
of antigen presentation become almost silent. The ac-TAP1/2 dimer suggests that conformational changes of
the transporter itself are essentially involved. A stable tion of gpUS6 at late times of infection may limit the
presentation of abundantly expressed structural anti-intercalation of gpUS6 with ER-luminal loops or mem-
brane-spanning segments of TAP1/2 might disturb con- gens of the virion like glycoprotein B. Indeed, the CTL
response against HCMV glycoprotein B was reportedformational changes leading to abrogation of transport.
In a minimal model, the inactivation of peptide trans- to be relatively weak and predominantly restricted by
MHC class II rather than MHC class I (Borysiewicz etport could be explained by the physical association of
gpUS6 and TAP without further factors being involved. al., 1988; Hopkins et al., 1996).
The multitude of stealth genes in the genomes of CMVWe have shown here that gpUS6 associates with the
multimeric TAP-associated complex rather than dis- may be required for several reasons: first, to cover the
protracted replication cycle, which takes at least 72 hrrupting it. This raises the possibility that the interaction
with TAP might not be sufficient to prevent peptide in the case of HCMV; and second, to compensate for
the opposite effects on MHC class I by cytokines liketransport but requires a cellular cofactor to mediate this
effect. Our results obtained with the tapasin-deficient IFNg, type I IFNs, and TNFa (Hengel et al., 1994; Hengel
et al., 1996) that are produced in infected tissues.Finally,.220 mutants and with HLA-A,B, C±deficient .221 mutant
cell indicate that at least these components are not the great demand to regulate the presentation function
of a high number of MHC class I alleles and their pep-essential for US6-mediated TAP inhibition. The role of
calreticulin and calnexin remains to be addressed. The tides in different cell types may have favored the diversi-
fication of the HCMV US genes and their functions. Ourdecreased presence of class I heavy chains in the TAP-
associated complex at late time points during HCMV screening procedure failed to identify US3 as an inhibitor
of antigen presentation (Ahn et al., 1996a; Jones et al.,infection (Hengel et al., 1996) further strengthens the
notion that class I heavy chains are dispensable for 1996). In fact, this could be due to a preference of the
US3 glycoprotein for certain human MHC class I allelesTAP inhibition by gpUS6. We favor the idea that gpUS6
directly contacts the TAP1/2 heterodimer, the latter be- (Jones et al., 1996).
Altogether, it appears a fascinating feature of HCMVing simultaneously associated with tapasin, MHC class
I/b2m, and calreticulin (Sadasivan et al.,1996). This phys- to use proteins encoded within a single cluster of related
genes, i.e. gpUS3 (Ahn et al., 1996a; Jones et al., 1996)ical interaction possibly involves a luminal region en-
compassing residues 78±96 of gpUS6 because an anti- controlling ER export of peptide loaded MHC class I
molecules on the one hand and gpUS6 controlling ERserum recognizing this region failed to coprecipitate
TAP (H. H., unpublished data) whereas the N-terminal import of peptides onthe other hand, toescape recogni-
tion by class I±restricted CTL.US6 epitope 20±29 allows coimmunoprecipitation as
shown here.
Available biochemical evidence suggests that cal-
Experimental Proceduresnexin dissociates from human class I-b2m heterodimers
before the latter associate with calreticulin and with ta- Cell Lines and Antibodies
pasin±TAP (Ortmann et al., 1994; Sadasivan et al., 1996; Human fetal lung fibroblasts, MRC-5 (Bio-Whittacker), in passages
6±16, 293 human kidney cells (ATCC CRL 1573), and human HeLaSolheim et al., 1997). Thus, calnexin does not participate
cells (ATCC CCL-2) were grown in Dulbecco's modified Eagle'sin the human TAP-associated complex, which is in clear
medium supplemented with 10% fetal calf serum, penicillin, strepto-contrast to findings in murine cells (Suh et al., 1994,
mycin, and 2 mM glutamine. The human lymphoblastoid cell lines1996). Therefore, it seems likely that gpUS6 binds to
LCL721.220 and LCL 721.221 (DeMars et al., 1985; Greenwood et
calnexin directly and independent of its association with al., 1994) were grown in RPMI 1640.
TAP complexes. Antibodies used were the following: MAb W6/32 recognizing HLA
Among the herpesviruses, CMVs have evolved the class I heavy chain/b2m dimers (Parham et al., 1979) was obtained
from the ATCC (HB 95); MAb HC-10 recognizing unassembled classmost extensive genetic repertoire to evade the MHC
I heavy chains with a preference for HLA-B and -C alleles but alsoclass I±restricted T lymphocyte response of the host.
HLA-A locus products (Stam et al., 1986); MAb BBM1 detectingMouse CMV expresses three early gene functions that
human b2m (ATCC HB-28); anti-CD44 MAb BA06 was from Onco-interfere with the MHC class I pathway of antigen pre- gene Science (Uniondale, NY); polyclonal rabbit antibodies to calre-
sentation (ThaÈ le et al., 1995; Kleijnen et al., 1997; Ziegler ticulin and BiP were from StressGen (Victoria, British Columbia,
et al., 1997). HCMV is expressing a cascade of four Canada); MHC I heavy chain rabbit antiserum was a kind gift from
Dr. H. L. Ploegh (Cambridge, MA); MAb AF8 to calnexin was a kindconsecutive US gene functions interrupting the class I
gift from Dr. M. Brenner (Boston, MA); anti-TAP1 MAb TAP1.28 andpathway of antigen presentation in a general manner.
anti-TAP2 MAbTAP2.70 have been described (Nijenhuis et al., 1996);The (IE) protein gpUS3, which is expressed in the very
polyclonal rabbit antibodies to tapasin (Rgp48N) (Sadasivan et al.,
beginning of permissive infection, impairs the transport 1996) were kindly donated by Dr. P. Cresswell (New Haven, CT).
of MHC class I complexes (Ahn et al., 1996a; Jones et Polyclonal rabbit antiserum was raised by immunization of rabbits
al., 1996). The US2- and US11-encoded glycoproteins with KLH-coupled synthetic peptides of amino acids 20±29 of the
US6 sequence.misdirect nascent class I heavy chains into the cytosol
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Viruses and Infection Condition was translated in the presence of microsomes. 50 pmol radioiodin-
ated peptide and 10 mM ATP were added in a final volume of 50 mlVirus stocks of HCMV strain AD169 were prepared as described
(Hengel et al., 1995). For infections, subconfluent monolayers of incubation buffer containing 0.1% BSA and incubated for 20 min at
378C. Then microsomes were lysed in 1% NP40 and glycosylatedfibroblasts were incubated with HCMV at an multiplicity of infection
of 5 and centrifuged at 800 3 g for 30 min to increase the efficiency peptides recovered with concanavalin A±Sepharose and quanti-
tated by g-counting.of infection. Infections of subconfluent HeLa cells with vaccinia virus
was performed at an multiplicity of infection of 3 overnight.
Metabolic Labeling and Immunoprecipitation
Immunoprecipitation was performed as described previouslyCytolytic Assay
The generation and maintenance of the CD81 CTL clone IE2 was (Hengel et al., 1995, 1996). In brief, semiconfluent layers of HeLa
cells were incubated with IFNg (500 U/ml) and labeled overnightdescribed in detail earlier (Goulmy et al., 1984). Clone JS132 was
kindly donated by Dr. Jannie Borst, Amsterdam. Target cells were with [35S]methionine and [35S]cysteine (1200 Ci/mmol; Amersham,
Braunschweig, Germany) at a concentration of 350 mCi/ml and lysedlabeled with 51Cr and tested in a 4 hr standard release assay with
graded numbers of effector cells. In all experiments, effector-to- in lysis buffer (140 mM NaCl, 20 mM Tris [pH 7.6], 5 mM MgCl2, 0.2
mM phenylmethylsulfonyl fluoride, leupeptin and leustatin) with 1%target ratios ranged from 20:1 to 0.8:1. Spontaneous 51Cr release in
the experiments given did not exceed 30% of the maximal release digitonin. 35S incorporation intoproteins was quantitated in all exper-
iments by liquid scintillation counting of a TCA precipitate or anvalues measured in the presence of 1% Triton X-100.
aliquot of the lysate. All lysates used for immunoprecipitation were
adjusted to ensure comparability in quantitative terms. After removalCloning and Expression of the HCMV US6 Gene and
of nuclei by centrifugation, lysates were precleared with preimmuneConstruction of a US6 Vaccinia Virus Recombinant
rabbit serum and protein A Sepharose. Immune complexes wereThe open reading frame of the US6 gene was cloned after
eluted with sample buffer and analyzed by 10%±15% PAGE. GelsPCR amplification from HCMV AD169 DNA (forward primer 59-CGCG
were treated with Amplify (Amersham), dried, and exposed to Bio-GGGGATCCGCCGCCATGGATCTCTTGATTCGTCTC-39, backward
MaxMR films (Kodak) at 2708C for 1±7 days. In some experiments,primer 59-CGCGGGTCTAGAGAATTCGCATCAGGAGCCACAACG
bands were quantitated using a Storm 860 Molecular Imager (Molec-TCG-39, resulting in an amplification product of 591 bp) into the
ular Dynamics, Sunnyville, CA). Digestion of immune complexespcDNAIneo expression vector (Invitrogen, San Diego, CA). The US6
with 2 mU per sample endo H (Boehringer Mannheim, Germany)construct containing the 39 24 bp FLAG sequence (Eastman Kodak,
was performed at 378C overnight.New Haven, CT) was obtained using the backward primer 59-CGC
In reimmunoprecipitation experiments, HeLa-US6 and controlCCCTCTAGATTACTACTTGTCATCGTCGTCCTTGTAGTCCT CGAG
cells were metabolically labeled overnight and lysed in 1% digitoninGATATCGGAGCCACAACGTCG AATGGGACG-39. The PCR product
lysis buffer followed by immunopreciptitation with anti-US6 antibod-was cloned into the 59 BamHI and 39 XbaI restriction sites of
ies. After washing precipitated proteins were dissolved in 1% NP40pcDNAIneo. Intervened by a short spacer (DILE), the hydrophilic
lysis buffer containing 1.5% SDS and heated to 658C for 35 min.FLAG sequence (DYKDDDDK) was fused to the US6 coding se-
After dilution to a final SDS concentration of 0.15% anti-US6 anti-quence. Human 293 kidney cells and HeLa cells were transfected
bodies were removed by two rounds of incubation with protein Awith plasmid DNA by calcium phosphate precipitation. Cell clones
Sepharose before reimmunoprecipitation with the appropriate anti-were selected in the presence of 0.5 mg/ml G418 and tested for
bodies and protein A Sepharose.gpUS6 protein expression by immunoprecipitation with US6-spe-
cific antibodies.
The open reading frame of the US6 gene sequence was cloned Photocrosslinking of Peptide
We used 107 SLO-permeabilized HeLa or HeLa-US6 cells for photo-after PCR amplification from HCMV AD169 DNA (forward primer
59-CGCGGGGGATCCGCCGCCATGGATCTCTTGATT CGTCTC-39, crosslinking with the radioiodinated peptide 125I-TYDNKTRA(Tpa)
(4-[trifuoromethyl-diazirinyl]phenylalanin) 48C by irradiation of thebackward primer 59-CGCGGGTCTAGAGAATTCGCATCAGGAGCC
ACAACGTCG-39 into the 59 BamHI and 39 EcoRI sites of plasmid suspension at 254 nm with an ultraviolet lamp as described (Nijen-
huis et al., 1996). After 5 min exposure, cells were lysed with bufferp7.5K131 (Schlicht and Schaller, 1989). This plasmid was used for
the construction of the vaccinia recombinant virus vacUS6 by ho- containing 1% NP40 for 30 min at 48C. Nuclei were pelleted for 5
min at 2000 3 g. TAP was immunoprecipitated from the supernatantmologous recombination with the vaccinia strain Copenhagen. The
recombinant vaccinia virus vacUS6 expressing US6 were selected and immunoprecipitated using MAbs TAP1.28 and TAP2.70 and
analyzed by 10% SDS-PAGE. As an inhibitor of peptide binding toby infecting tk-143 cells as described (Volkmer et al., 1987).
TAP, recombinant ICP47 protein (FruÈ h et al., 1995) was used at a
concentration of 30 mg/ml.Peptide Translocation Assay
The transport assays were performed essentially as described
(Neefjes et al., 1993; Momburg et al., 1994b). Peptides 67 (RYWA Flow Cytometry
HeLa cells were preincubated in 5% goat serum and then stainedNATRSF), 600 (TNKTRIDGQY), and 802 (RRYQNSTEL) were radio-
labeled with 125I by chloramine-T±catalyzed iodination. After trypsin- with MAbs. Bound antibodies were visualized by addition of fluores-
cein-conjugated goat anti-mouse antibodies (Dianova, Hamburg,ization, HCMV-infected fibroblasts, vaccinia virus±infected HeLa
cells, or transfectants were permeabilized with SLO (2.5 U/ml). Next, Germany). As a negative control cells were incubated with the sec-
ond antibody alone. A total of 104 cells was analyzed for each histo-1.25 3 106 cells per sample were incubated with peptide (1 mM) and
10 mM ATP in 0.1 ml incubation buffer (130 mM KCl, 5 mM HEPES gram on a FACScan IV (Becton Dickinson, San Jose, CA).
[pH 7.3], 10 mM NaCl, 1 mM CaCl2, 2 mM EGTA, 2 mM MgCl2) for
20 min at 378C. Following lysis in 1% NP40, the glycosylated peptide Confocal Laser Scanning Microscopy
fraction was isolated with 30 ml concanavalin A±Sepharose slurry Subconfluent layers of HeLa-US6 cells were grown on glass cov-
and quantified by g-counting. Concanavalin A recovered counts per erslips. Cells were rinsed with phosphate-buffered saline (PBS) and
minute were expressed as percentage of input counts per minute. fixed with 3% (wt/vol) paraformaldehyde in PBS for 20 min. After
blocking unreactable aldehyde groups with 50 mM NH4Cl and 20
mM glycine in PBS, cells were permeabilized with 0.2% Triton X-100Preparation of Microsomes, In Vitro Translations,
and Peptide Transport Assay in PBS. To block nonspecific binding of antibodies, coverslips were
incubated in 0.2% (wt/vol) fish skin gelatin in PBS (Sigma, St. Louis,Microsomes were prepared according to Scheele (1983). In vitro
translations were performed using microsomes from the human MO). Double immunofluorescence was performed by incubating pri-
mary antibodies together with 0.2% gelatin in PBS for 45 min. Afterlymphoblastoid cell lines LCL721.220 and LCL 721.221. US6 mRNA
was transcribed from pcDNAIneo-US6 using T7 RNA polymerase extensive washing with PBS, the cells were incubated again with
0.2% gelatine and stained with second antibodies, fluorescein iso-(Promega, Heidelberg, Germany) according to the instructions of
the supplier. US6 mRNA or, for control, S. cerevisiae a-factor mRNA thiocyanate (FITC)±conjugated goat anti-rabbit immunoglobulin G
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(IgG) (Dianova) and rhodamine-conjugated goat anti-mouse IgG (Di- J., Korn, N., Sidwell, B., and Orr, H.T. (1985). Mutations that impair
a post-transcriptional step in expression of HLA-A and -B antigens.anova), in 0.2% gelatine for 45 min. After washing with PBS, the glass
coverslips were mounted on glass slides with Histosafe (Camon, Proc. Natl. Acad. Sci. USA 82, 8183±8187.
Wiesbaden, Germany). The mounted cells were analyzed with a FruÈ h, K., Ahn, K., Djaballah, H., Sampe, P., van Endert, P.M., Tampe,
laser scanning confocal microscope (Leitz DM IRB, Leica Scanner R., Peterson, P.A., and Yang, Y. (1995). A viral inhibitor of peptide
TCS 4D). transporters for antigen presentation. Nature 375, 415±418.
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